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Introduction
Antiphospholipid antibodies (aPLs) are found in a wide range of 
clinical conditions including autoimmune disorders, infections 
(viral, bacterial and parasitic), drug exposure, lymphoproliferative 
disorders and in a proportion of otherwise healthy individuals.1 
These antibodies belong to a heterogeneous group of auto-
antibodies usually directed against negatively charged 
phospholipids bound to plasma proteins, particularly beta-2-
glycoprotein I (β2GPI). The aPLs result in prolongation of the 
clotting times of phospholipid-dependent coagulation assays 
in the laboratory, such as the activated partial thromboplastin 
time (aPTT) and dilute Russell's viper venom time (dRVVT). 
Despite the prolonged clotting times in vitro, patients with 
aPLs are predisposed to venous or arterial thromboses, as well 
as pregnancy loss.2 The in vitro coagulation cascade, including 
the phospholipid dependent components, and laboratory 
assays used to assess these pathways, is depicted in Figure 1.3 
Phospholipids play an integral role in progression of coagulation 
to fibrin clot formation. 
Antiphospholipid syndrome (APS) is an acquired autoimmune 
disorder and represents the most frequently encountered 
thrombophilic condition in females of childbearing age.4 APS is 
characterised by thromboses and/or adverse obstetric outcomes 
in a patient with persistent aPLs. These aPLs can be demonstrated 
by functional lupus anticoagulant (LA) tests and/or by enzyme-
linked immunosorbent assay (ELISA) methods, which detect 
antibodies directed against various proteins including cardiolipin 
The lupus anticoagulant (LA) refers to the prolongation of certain coagulation tests due to the action of heterogenous autoantibodies. 
However, the LA is a misnomer since it is associated with thrombosis in vivo, and most commonly is detected as an incidental, transient 
laboratory finding associated with conditions such as autoimmune diseases, infections and even in healthy individuals. Repeatedly 
positive LA testing in the setting of thrombotic and/or obstetric complications is required to diagnose the antiphospholipid syndrome 
(APS). This review intends to provide clarity on LA testing in the South African context and to provide a national guideline in order to 
standardise LA testing, interpretation and reporting of results.
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Table I: Revised international consensus diagnostic criteria for 
definitive anti-phospholipid syndrome8
At least one laboratory and one clinical criterion must be met before 
a diagnosis of antiphospholipid syndrome (APS) can be made. 
Clinical and laboratory criteria cannot be more than five years apart.
Laboratory criteria* Clinical criteria
1. Positive plasma lupus 
anticoagulant demonstrated 
on two occasions at least 12 
weeks apart**.
2. Presence of anticardiolipin 
antibody of either IgM and/
or IgG isotype present at 
medium or high titres (i.e. 
> 40 MPL or GPL; or > 99th 
percentile) on two occasions 
measured at least 12 weeks 
apart†.
3. Presence of anti-β2 
glycoprotein I antibody of 
either IgM and/or IgG with a 
titre > 99th percentile, on two 
occasions measured at least 
12 weeks apart†.
Vascular thrombosis 
• One or more objectively 
confirmed venous, arterial 
and/or small vessel thrombosis 
(in the absence of significant 
vessel wall inflammation‡.) 
Pregnancy complications 
• One or more unexplained 
deaths of a morphologically 
normal foetus at ≥ 10 weeks 
gestation. 
• One or more premature 
births of a morphologically 
normal foetus before 34 weeks 
gestation and secondary to 
pre-eclampsia/eclampsia 
or features of placental 
insufficiency. 
• Three or more spontaneous 
unexplained pregnancy losses 
before 10 weeks gestation 
with no identifiable secondary 
cause. 
* Patients should be classified according to the number of laboratory criteria met. 
** Lupus anticoagulant should be detected according to international guidelines.9,10
† Measured by a standardised enzyme linked immunosorbent assay (ELISA).  
‡ Superficial thrombosis is excluded. 
MPL – IgM antiphospholipid units; GPL – IgG antiphospholipid units. 
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(aCL) and beta-2-glycoprotein I (anti-β2GPI). Thrombotic events 
may occur anywhere in the vascular tree, and affect vessels 
of all sizes (small to large) in both the arterial and/or venous 
compartments, in any organ system or tissue of the body (Figure 
2). Adverse pregnancy outcomes occur secondary to placental 
insufficiency, which may result in recurrent early pregnancy 
loss (before 10 weeks gestation), pre-eclampsia/eclampsia with 
premature birth, or late foetal demise.2,5,6  
The pathogenesis of APS remains poorly understood. Some 
individuals with persistent aPLs do not develop clinical 
complications suggesting that additional triggers are required 
such as an inflammatory insult, or host susceptibility to 
thrombotic complications.2 Vascular endothelial dysfunction and 
activation of inflammatory responses including the complement 
system play an important role in the pathogenesis of APS.2,7 The 
international diagnostic criteria for APS stipulate the requirement 
for at least one clinical and one laboratory criterion to be fulfilled 
on two occasions at least 12 weeks apart (Table I).8 A schematic 
representation of the diagnostic criteria for APS is presented in 
Figure 3.
Antiphospholipid syndrome may occur in isolation (primary 
APS) or secondary to an underlying disorder such as systemic 
lupus erythematosus (SLE), rheumatoid arthritis, haematological 
malignancy or a solid tumour.2,7,11 Associated features other 
than thromboses include thrombocytopenia, livedo reticularis, 
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Figure 1: The in vitro coagulation cascade. Adapted from Levine et al3
TF – tissue factor; F – coagulation factor; a – activated; HMWK – high-molecular-weight kininogen; PL – phospholipid. * PT is converted to the international normalised ratio 
(INR) 
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Figure 3: A schematic representation of the international diagnostic 
criteria for antiphospholipid syndrome8
aCL – anticardiolipin antibodies; anti-β2GPI – anti-beta 2-glycoprotein I antibodies.
Figure 2: Haematoxylin and eosin (H&E) image (x 20 magnification) 
showing adherent thrombus (A) in the deep vein (B) of the left leg, in a 
patient in whom a pulmonary embolus was found at autopsy
A
B
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valvular heart disease, neurological manifestations and 
nephropathy.2,11,12 Catastrophic antiphospholipid syndrome 
(CAPS) is a rare and life-threatening form of APS, occurring in 
< 1% of cases.7 Preliminary diagnostic criteria for CAPS include 
persistent aPLs in a patient with multi-organ involvement 
affecting three or more sites simultaneously or within seven 
days of each other, and with histological evidence of small vessel 
occlusion with or without vasculitis.13 
The laboratory diagnosis of these antibodies needs to be made 
according to established international criteria in accredited 
laboratories. Patients diagnosed with APS are typically placed on 
lifelong anticoagulation therapy, which has considerable risks. 
Testing for antiphospholipid antibodies, including the LA, aCL 
and anti-β2GPI, is recommended where the clinical diagnostic 
criteria for APS are met; or in otherwise healthy individuals with 
an unexpected prolonged activated partial thromboplastin 
time (aPTT) that does not correct with mixing studies.9,12 The 
anticoagulant effect associated with aPLs represents an in vitro 
phenomenon caused by the action of these autoantibodies 
on the proteins of the coagulation cascade which results 
in prolonged clotting times in the laboratory. According to 
international criteria,11 two different phospholipid dependent 
clotting assays must be performed when testing for the presence 
of aPLs and only one of these assays is required to be positive to 
confirm the diagnosis.  
The aim of this review is to provide a national guideline for lupus 
anticoagulant (LA) testing in the South African context and is 
intended to standardise testing, interpretation and reporting 
of results. Key aspects of the pre-analytical, analytical and post-
analytical phases of testing are highlighted.
Laboratory testing for a lupus anticoagulant and 
antiphospholipid antibodies 
Obtaining both functional (clot-based) assays and solid phase 
immuno-assays, namely enzyme-linked immunosorbent assays 
(ELISA), is needed for the diagnosis or exclusion of APS. To assess 
for the presence of aPLs, testing for the LA, aCL (IgM and/or IgG) 
and anti-β2GPI (IgM and/or IgG), is indicated. Positive test results 
should be documented on two occasions at least 12 weeks apart 
to rule out transient positive and clinically insignificant results.5 
Sample preparation
For coagulation testing, fresh venous blood samples obtained 
via atraumatic venepuncture must be collected in citrate tubes 
(0.109M trisodium citrate; 9-parts whole blood to 1 part citrate). 
Double centrifugation at 4 000 rpm (2 000 g) for 15 minutes 
at room temperature (15 to 25 0C) should be performed as 
soon as possible, and ideally within one hour of collection to 
ensure a platelet count of < 10 x 109/L prior to LA testing.6,9,11,14 
This centrifugation step removes platelets which are a source 
of phospholipid, as even low concentrations of phospholipid 
interfere with LA testing. Furthermore, centrifugation is per-
formed at room temperature in order to avoid platelet activation 
and fragmentation, both of which will increase the phospholipid 
content of the sample and shorten the clotting times, thus 
leading to a false negative LA test result. Ultracentrifugation of 
the sample should be avoided, as it generates phospholipid rich 
microparticles.13,14 After centrifugation, the plasma is removed 
without disturbing the white cell and platelet rich buffy layer. The 
plasma is aliquoted and frozen at between -70 and -80 oC, unless 
testing will be performed within four hours of collection. On the 
day of testing, the frozen aliquoted plasma samples are thawed 
at 37 oC in a water bath for approximately five minutes and 
mixed gently before testing. Testing should not be performed 
on samples that have undergone more than one freeze-thaw 
cycle.6,9,12,13 
Functional LA testing work flow
A consensus, national LA testing flowchart is presented in Figure 
4. This flowchart highlights the key steps in functional laboratory 
testing required for the identification of an LA. 
Baseline coagulation tests for the investigation of an LA 
(or a lupus anticoagulant)
An international normalised ratio (INR) and activated partial 
thromboplastin time (aPTT) should be routinely performed. We 
therefore recommend that at least two citrate tubes appropriately 
filled to the minimal indicator line are submitted in order to 
ensure sufficient sample for both the baseline coagulation 
testing and LA testing. These baseline coagulation tests exclude 
patient exposure to anticoagulants or factor deficiencies that 
may influence interpretation of LA test results. Testing for LA is 
advised prior to starting anticoagulant therapy, or at least three 
weeks after their discontinuation, since anticoagulant therapy 
may interfere with interpretation of LA testing results. If the 
aPTT is prolonged, a 50:50 mixing study with normal plasma is 
necessary. If an LA is present in the sample, the aPTT will typically 
not correct with mixing, but if a factor deficiency is the cause for 
the aPTT prolongation, it will. When the aPTT is prolonged and 
does not correct with mixing, a thrombin time (TT) is advised to 
exclude the presence of unfractionated, and to a lesser extent 
low molecular weight heparin or direct thrombin inhibitors.12 
Many dilute Russell's viper venom time (dRVVT) reagents do 
however include a heparin neutralising agent that should be 
sufficient to neutralise a prophylactic dose of low molecular 
weight heparin (LMWH).9,11 
The dRVVT assay utilises reagents which directly activate Factor 
X (FX) in the common coagulation pathway, an action similar 
to that of Russell's viper snake venom (see Figure 1). The direct 
activation of FX leads to fibrin clot formation, and deficiency in 
the other clotting factors that usually activate FX will therefore 
not affect dRVVT results.10 The International Society on 
Thrombosis and Haemostasis (ISTH) recommends that LA testing 
should be performed only if the INR is < 1.5. It recommends that 
where clinically appropriate LA testing should be postponed 
until warfarin therapy has been safely stopped and the INR has 
normalised. Alternatively, LA testing can be performed after 
three months of adequate warfarin therapy by switching the 
patient to appropriate doses of LMWH. Warfarin should only be 
stopped to allow LA testing, if testing is essential on clinical or 
therapeutic grounds.9,11 The direct oral anticoagulants (DOACs), 
including dabigatran, rivaroxaban, edoxaban and apixaban, also 
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interfere with LA testing. The dRVVT is particularly sensitive to 
their interference and LA testing is therefore not recommended 
while the patient is on DOAC therapy.16,17
Functional assays to detect a lupus anticoagulant
International criteria require that two phospholipid-dependent 
coagulation assays, based on different test principles, are used 
to diagnose an LA.9,10,12,13 Most guidelines recommend using the 
dRVVT, as well as an aPTT done with a lupus sensitive reagent 
(PTT-LA), as explained below. If either test result is prolonged and 
fails to correct by mixing with either normal pooled plasma (NPP) 
or commercial normal plasma, while correcting with the addition 
of excess phospholipid, the LA test is considered positive.9,10 
In summary, three steps are indicated to investigate for the 
presence of LA:9,13 
1. a screening step with low phospholipid in the test system; 
2. a confirmatory step with excess of phospholipid in the test 
system; and
3. a mixing step.
The PTT-LA test may only include a screening and mixing step i.e. 
step 1 and step 3 above, without a confirmatory phospholipid-
rich step i.e. step 2, if no reagent with excess phospholipid is 
available to the testing laboratory. Most laboratories in South 
Africa do not have a PTT-confirm (phospholipid rich) reagent 
readily available.  
A. LA sensitive aPTT (PTT-LA)
The ‘LA sensitive’ assay refers to the low concentration of 
phospholipid in the test system, which is relatively insensitive to 
Figure 4: Proposed national LA testing flowchart
LA – lupus anticoagulant; INR – international normalised ratio; aPTT – activated partial thromboplastin time; TT – thrombin time; PPP – platelet poor plasma;  
PL – phospholipid; aPLs – antiphospholipid antibodies. 
* Normal pool: control normal plasma. ** The effect of excess phospholipid used in the confirm step of the dRVVT can also be measured using the equation [(screen clotting 
time – confirm clotting time)/screen clotting time) x 100], where a % correction above the local cut-off value confirms the presence of LA.9 † Other inhibitors such as FVIII 
specific inhibitor or heparin may cause these results. 
Routine coagulation tests performed prior to functional LA testing:
 INR > 1.5 on warfarin therapy → Postpone LA testing. Test after warfarin is ceased and INR < 1.5.
Functional LA testing:
A aPTT using LA sensitive reagent (PTT-LA):
1. Patient  PPP
2. PTT-LA  
reagent
Step 1: Screen 
Ratio of patient aPTT/Normal 
pool aPTT*
• Ratio > 1.2 (or < 70% 
correction using the 
percent correction 
formula)15
• perform mixing study 
(step 2)
• Ratio < 1.2: assay negative 
for LA.
Step 2: Mixing study
50:50 mix using patient plasma and pooled normal plasma
Ratio of mixed plasma aPTT/Normal pool aPTT:
• Ratio ≥ 1.2: suggestive of an inhibitor such as LA but must exclude 
heparin contamination → Thrombin time (TT)
 ◦ TT prolonged and corrects with protamine 
Confirms heparin. LA testing unreliable. Repeat testing  
> 2 weeks after ceasing anticoagulation therapy.
 ◦ TT normal and aPTT does not correct 
Suggests the presence of an inhibitor such as LA → dRVVT
• Ratio < 1.2: negative for LA; consider a coagulation factor deficiency. 
B       Dilute Russell's viper venom time (dRVVT):
Step 1: dRVVT screen (low phospholipid)
Ratio of clotting times in seconds: 
Patient sample/Normal pool = A
• < 1.2: negative for LA 
• > 1.2: proceed to step 2 which includes the addition of 
excess phospholipid to the test system (confirm reagent). 
Step 2: dRVVT confirm (excess phospholipid)
Ratio of clotting times in seconds: 
Patient sample/Normal pool** = B
• If B < 1.2: perform normalised ratio (NR) = A/B 
Interpret results of NR as follows: 
NR result: Interpretation:
< 1.20 Negative for LA
> 1.20–1.49 Weakly positive
    1.50–2.00 Moderately positive
> 2.00 Strongly positive  
• If B > 1.2: proceed to step 3
Step 3: Mix screen (low phospholipid)
50:50 mix of patient plasma and pooled normal plasma.
Ratio of clotting times in seconds: 
Patient mix sample/Normal pool = C
• < 1.2: LA is excluded; cause of the prolonged clotting time 
likely coagulation factor deficiency. 
• > 1.2: proceed to step 4 which includes the addition of 
excess phospholipid to the test system (confirm reagent).
Step 4: Mix confirm (excess phospholipid)
50:50 mix of patient plasma and pooled normal plasma. 
Ratio of clotting times in seconds: 
Patient mix sample/Normal pool = D
• If D < 1.2: perform NR = C/D 
Interpret results of NR as follows: 
NR result: Interpretation:
< 1.20 Negative for LA
> 1.20–1.49 Weakly positive
    1.50–2.00 Moderately positive
> 2.00 Strongly positive  
• > 1.2: cannot interpret for a LA due to another inhibitor.†
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low concentrations of heparin or factor deficiency.9,14 The result 
is reported as a ratio between the patient’s aPTT (PTT-LA) and 
an aPTT obtained with the NPP (or commercial normal plasma). 
Most laboratories perform only a screening test, followed by 
a mixing study if the screen/normal pool aPTT ratio is ≥ 1.2 
(Figure 4). A positive result (≥ 1.2) after aPTT mixing studies 
suggests the presence of an inhibitor such as an LA, high dose 
heparin therapy, sample contamination or more rarely a specific 
inhibitor to a coagulation factor in the intrinsic pathway (most 
commonly a Factor VIII inhibitor).9
A number of formulae including the percent correction 
formula18,19 and the Rosner index,20 may be used to assess the 
difference in the clotting times obtained before and after 
performing mixing studies. Certain cut-off values are suggestive 
of an inhibitor,15 however none of these formulae are 100% 
sensitive or specific. When using the percent correction formula, 
a cut-off value of < 70% suggests the presence of an inhibitor; 
whereas > 70% correction suggests a factor deficiency.18,19 In one 
large study, the percentage correction was shown to be slightly 
more sensitive to detecting the LA than the Rosner index (95% 
versus 93%).15
  Percent correction =
 test aPTT – 50:50 mix aPTT    x 100                                                   test aPTT – normal aPTT
 Rosner index =    50:50 mix aPTT – normal aPTT   x 100                                                              test aPTT 
B. Dilute Russell's viper venom time (dRVVT)
The dRVVT (Figure 1) assesses the effect of LA on the common 
coagulation pathway via the direct activation of FX in a calcium-
dependent manner. Activation of FX by the procoagulant snake 
venom-based reagent is independent of the concentration of 
phospholipid in the test system. Thus testing under phospholipid 
poor (screen step) and phospholipid rich (confirm step) conditions 
is feasible.10 If the screen step ratio result is increased (≥ 1.2), 
the confirm step excludes the presence of an LA by assessing 
phospholipid dependence, and further defines the strength of 
LA activity.9,12 Phospholipid dependence is demonstrated by a 
significant shortening in the clotting time in the confirm step as 
compared to the screen step, and a normalised LA ratio reported 
to two decimal places should be calculated:9,10 
Normalised LA ratio = Screen ratio A                                                Screen ratio B
Depending on the results of the screen and confirm steps, a 
mixing step may be needed to further assess for other causes of 
the prolonged clotting times, such as clotting factor deficiencies 
or the presence of another inhibitor such as heparin. The mixing 
step is indicated if the confirm step ratio is ≥ 1.2. Mixing studies 
are performed by adding either NPP or commercial normal 
plasma in a 1:1 ratio to the patient’s plasma, which is then done 
without a pre-incubation step, within 30 minutes of preparing the 
mix. The NPP (or commercial normal plasma) supplements any 
deficient clotting factor to at least 50% of normal. Therefore, NPP 
(or commercial normal plasma) should normalise the clotting 
time of the mixing study in the absence of an inhibitor, and if the 
original prolongation in the clotting time was due to coagulation 
factor deficiency. If the clotting time remains prolonged at a ratio 
of ≥ 1.2 compared to that of NPP (or commercial normal plasma), 
the mixed plasma must be analysed with a phospholipid rich 
confirm reagent to detect the presence of an LA in combination 
with a factor deficiency. It is important to note that a very weak 
LA may correct with the mixing study prior to the confirmation 
step, resulting in a false negative LA result.9,12 
Reporting of results 
Patient results for the screen, confirm and mixing steps are 
reported as a ratio between the clotting times obtained for 
the patient’s plasma and that of the NPP (or commercial 
normal plasma) (Figure 3).9-11 Interpretive reporting and 
recommendations for repeat testing should be provided as 
indicated.9,10 The reports should clearly indicate whether an LA 
was detected or not, which method was used, and which cut-off 
values were used.10,11 Mixing studies should only be performed if 
indicated. In the rare instance where a ratio of ≥ 1.2 is reported 
Table II: Dilute Russell's viper venom time (dRVVT) results and their interpretations9
Patient plasma Patient/normal pooled plasma mix (1:1)
Interpretation
Screen Confirm Screen NR Screen mix Confirm mix Mix NR 
< 1.2 - - - - - LA not detected
≥ 1.2 < 1.2 < 1.2 - - - LA not detected
≥ 1.2 < 1.2 ≥ 1.2 - - -
LA detected (state whether weak, moderate or strong as 
per NR). Repeat after 12 weeks once off anticoagulation 
to demonstrate persistence / significance 
≥ 1.2 ≥ 1.2 - < 1.2 - - LA not detected. Exclude clotting factor deficiency.
≥ 1.2 ≥ 1.2 - ≥ 1.2 < 1.2 < 1.2 LA not detected
≥ 1.2 ≥ 1.2 - ≥ 1.2 < 1.2 ≥ 1.2
LA detected (state whether weak, moderate or strong as 
per NR). Repeat after 12 weeks once off anticoagulation 
to demonstrate persistence / significance
≥ 1.2 ≥ 1.2 - ≥ 1.2 ≥ 1.2
- 
Unsuitable for interpretation of a LA due to the presence 
of another inhibitor such as heparin or coagulation 
factor specific inhibitor. Advise repeat testing after 
anticoagulation therapy has been ceased.
NR – normalised ratio; LA – lupus anticoagulant
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for the dRVVT confirm step (step 2), an automatically calculated 
normalised LA ratio result should be suppressed if it is displayed 
by the laboratory information system (LIS). If the mixing step 
ratio is < 1.2, a weak LA may be present and the dRVVT should 
be reported as suggestive of a weak LA, with follow-up testing 
advised once the patient no longer requires anticoagulation.14 
Various dRVVT results and their appropriate interpretations are 
provided in Table II.
Quality assurance and establishing cut-off values
Internal controls, manufacturer’s normal (LA negative) and 
abnormal (LA positive) controls, or patient samples with known 
LA positive or negative results, should be analysed with each 
batch of patient tests to ensure the reporting of accurate results. 
These controls should be handled like patient samples. Results of 
the normal control should fall within the laboratory-derived cut-
off values for a negative LA.11 Ideally, local population-specific 
cut-off values for a positive result should be determined by each 
laboratory because of local differences in reagents and analysers 
used. This is not always feasible because of costs, labour and 
availability of reference controls. It is therefore acceptable to 
use manufacturer-established cut-off values, or established 
cut-off values from another laboratory which uses the same 
reagents, analyser and analytical protocol. A cut-off value 
should be established for each LA test. Commonly a ratio of the 
clotting time of the sample vs that of NPP (or commercial normal 
plasma) of ≥ 1.2 for both the aPTT (PTT-LA) and dRVVT is taken as 
indicative of an inhibitor, such as an LA.8,13 
Table III highlights some key recommendations for avoiding false 
positive and negative LA test results.6 Testing during the acute 
phase of illness should be avoided. Fibrinogen and Factor VIII are 
both acute phase reactants and elevated levels of either one (or 
both) as seen during infection, inflammation and pregnancy, will 
shorten the clotting times of clot-based assays and can interfere 
with LA testing. In sepsis or inflammation there is an increase 
in circulating phospholipid rich platelet microparticles which 
may also interfere with the detection of LA. Thus testing in the 
acute phase of illness should be avoided as it may result in a false 
negative result.6,10 
Solid phase immuno-assays 
An ELISA is typically used to detect anti-β2GPI and aCL antibodies 
in serum or platelet poor plasma (PPP). The isotype and titres 
should be determined and reported.21 One or both antibodies 
may be detected with or without a positive LA result and only 
one of these tests needs to be positive to satisfy diagnostic 
criteria for APS. Results reported by different laboratories vary 
enormously and likely reflect the differences in pre-, post- and 
analytical conditions, the reference materials used for calibration, 
and imprecision of the method in use.12,21 The reader is referred 
to the latest guidelines from the Scientific and Standardisation 
Committee (SSC) of the International Society on Thrombosis and 
Haemostasis (ISTH) on testing for antiphospholipid antibodies 
with solid phase assays.21 
Summary
This guideline aims to standardise testing, interpretation and 
reporting of functional LA testing in South Africa. Testing for 
an LA can be challenging as the aPLs are heterogeneous and 
anticoagulant therapy can interfere with testing. Functional 
coagulation tests for an LA, and ELISA assays for anti-β2GPI and 
aCL antibodies must be performed as part of the laboratory 
investigation for aPLs. An aPTT obtained with LA sensitive 
reagents (PTT-LA) and dRVVT are both required to detect an LA 
since these are two phospholipid-dependent coagulation tests 
based on different principles. Because of the significant clinical 
implications of the LA results, testing should only be performed 
by trained, competent staff in accredited laboratories with 
appropriate internal controls and EQA programmes. 
Baseline coagulation and functional LA tests should be per-
formed prior to starting anticoagulation, or after a sufficient 
period off anticoagulant therapy. Other important pre-
analytic factors to consider include the collection of blood 
samples (atraumatic venepuncture, adequate sample volume 
and collection in a 0.109M trisodium citrate tube), double 
centrifugation of samples at room temperature to obtain PPP 
with a platelet count of < 10 x 109/L, quick freezing if samples 
are not analysed within four hours, correct thawing technique 
of frozen aliquots and gentle mixing of samples prior to analysis. 
Figure 4 provides a consensus national LA testing flowchart. 
This flowchart highlights the key steps in functional laboratory 
testing for an LA. The interpretation and reporting of results as 
documented in this guideline, as well the caveats listed in Table 
II, should be kept in mind.  
Table III: Recommendations for avoiding false positive and negative 
LA test results6
To avoid false positive results:
1. Both a LA sensitive aPTT, and dRVVT should be performed.
2. Screen-, confirm- and mix steps should be performed as indicated, 
and local cut-off values should be determined by each laboratory.
3. Fresh NPP prepared from at least 20 normal donor plasmas with an 
equal male and female distribution should ideally be used with 
each new batch of samples tested.
4. ELISA assay for both aCL and anti-β2GPI should be performed 
together with LA testing.
5. A positive LA result should be documented on two occasions at 
least 12 weeks apart to confirm significance.
6. LA testing should be performed prior or after stopping 
anticoagulation therapy. Samples should be rejected if the INR is 
> 1.5, unless dilutions are performed.
7. Adequate IQC testing is needed for each test batch as well as 
participation in an EQA programme.
To avoid false negative results: 
1. Avoid testing during the acute phase of illness.
2. Ensure correct plasma handling which includes the appropriate 
collection of blood, double centrifugation to obtain PPP, quick 
freezing if samples are not analysed within 4 hours, appropriate 
thawing technique and gentle mixing of samples prior to analysis. 
3. Perform the dRVVT confirmatory step prior to mixing studies to 
detect a weak LA.
LA – lupus anticoagulant; aPTT – activated partial thromboplastin time; dRVVT – dilute 
Russell's viper venom time; NPP – normal pooled plasma; PPP – platelet poor plasma; 
aCL – anticardiolipin antibodies; anti-β2GPI – anti-beta 2 glycoprotein I; INR – international 
normalised ratio; IQC – internal quality control; EQA – external quality assessment.
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